A 62-year-old male smoker with COPD (GOLD stage 2, FEV₁ 50–79% predicted) and no exacerbations in the past year presents for routine management. Which drug class is the first-line pharmacological treatment for his stable disease?

Explanation

## First-Line Management of Stable COPD (GOLD Stage 1–2) **Key Point:** For patients with COPD and no exacerbation history, a single long-acting bronchodilator (LABA or LAMA) is first-line. LAMA monotherapy is preferred as initial therapy in many guidelines because of superior efficacy in reducing exacerbations and improved symptom control compared to LABA alone. **High-Yield:** GOLD 2023 recommends: - **Stage 1 (mild):** Short-acting bronchodilator PRN - **Stage 2–3 (moderate–severe):** Long-acting bronchodilator (LABA or LAMA) ± ICS if exacerbation history - **Stage 4 (very severe):** Triple therapy (LABA + LAMA + ICS) or dual therapy depending on exacerbation phenotype ## Comparison of First-Line Options | Drug Class | Mechanism | Exacerbation Reduction | First-Line Role | Notes | |---|---|---|---|---| | **LAMA** | M3 antagonist | Superior | **Yes** | Preferred initial monotherapy | | **LABA** | β₂ agonist | Moderate | Yes (alternative) | Often combined with LAMA | | **ICS** | Anti-inflammatory | Only if exacerbation history | No monotherapy | Risk of infection if used alone | | **Theophylline** | Phosphodiesterase inhibitor | Minimal | No | Narrow therapeutic index; reserved for resource-limited settings | **Clinical Pearl:** ICS monotherapy is NOT recommended in COPD without a history of exacerbations, as it increases infection risk (especially *Mycobacterium tuberculosis*) without mortality benefit. Theophylline is obsolete in modern COPD management due to poor tolerability and drug interactions. **Mnemonic:** **LAMA-First** — Long-Acting Muscarinic Antagonist is the preferred Monotherapy for Asymptomatic/stable disease. [cite:GOLD 2023 Report, Harrison 21e Ch 254]